Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: A prospective study

Journal of the American Society of Nephrology

Volumn 7, Issue 1, 1996, Pages 140-144

  Teruel, José L ^a   Marcen, Roberto ^a   Navarro Antolin, Javier ^a   Aguilera, Abelardo ^a   Fernandez Juarez, Gemma ^a   Ortuño, Joaquín ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Anemia; Erythropoietin; Hemodialysis; Nandrolone decanoate

Indexed keywords

ANDROGEN; NANDROLONE DECANOATE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030060615     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v71140     Document Type: Article

References (28)

1. DeGowin RL, Lavender AR, Forland M, Charleston D, Gottschalk A: Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone. Ann Intern Med 1970;72:913-918.
2. Richardson JR Jr, Weinstein MB: Erythropoietic response of dialyzed patients to testosterone administration. Ann Intern Med 1970;73:403-407.
3. García-Otero G, Aguilera A, Teruel JL, Marcén R, Gámez C, Ortuño J: Indicaciones actuales de los anabolizantes en el tratamiento de la anemia del enfermo dializado. Nefrología 1993;13[Suppl 1]:40.
4. Williams JS, Stein JH, Ferris T.H.: Nandrolone decanoate therapy for patients receiving hemodialysis. Arch Intern Med 1974;134:289-292.
5. Hendler ED, Goffinet JA, Ross S, Longnecker RE, Bakovic V: Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. N Engl J Med 1974;291:1046-1051.
6. Buchwald D, Argyres S, Easterling RE, et al.: Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. Nephron 1977;18:232-238.
7. Davies M, Muckle TJ, Cassells-Smith A, Webster D, Kerr DNS: Oxymetholone in the treatment of anemia in chronic renal failure. Br J Urol 1972;44:387-394.
8. Cattran DC, Fenton SSA, Wilson DR, Oreopoulos D, Shimizu A, Richardson RM: A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney Int 1977;12:430-437.
9. Naik RB, Gibbons AR, Gyde OHB, Harris BR, Robinson BHB: Androgen trial in renal anemia [Abstract]. Kidney Int 1978;14:109A.
10. Mirahmadi MK, Vaziri ND, Gorman JT: Controlled evaluation of hemodialysis patients on nandrolone decanoate (ND) vs testosterone enanthate (TE). Trans Am Soc Artif Intern Organs 1979;25:449-453.
11. Teruel JL, Marcén R, Navarro JF, Villafraela JJ, Fernández Lucas M, Liaño J: Evolution of serum erythropoietin after androgen administration to hemodialysis patients: A prospective study. Nephron 1995;70:282-286.
12. Teruel JL, Quereda C, Martín E, Orofino L, Liaño F, Ortuño J: Tratamiento de la anemia no ferropénica en hemodialisis mediante anabolizantes. Nefrología 1983;3: 273-278.
13. Fried W, Jonasson O, Lang G, Schwartz F: The hematologic effect of androgen in uremic patients: Study of packed cell volume and erythropoietin responses. Ann Intern Med 1973;79:823-827.
14. Neff MS, Goldberg J, Slifkin RF, et al.: A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 1981;304:871-875.
15. Aguilera A, Teruel JL, Navarro-Antolin J, et al.: Has androgen a role in the erythropoietin era? J Am Soc Nephrol 1994;5:430.
16. Pascual J, Teruel JL, Marcén R, Liaño F, Ortuño J: Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs 1992;15:393-396.
17. Raine AEG, Roger SD: Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991;18:76-83.
18. Soliman G, Oreopoulos DG: Anabolic steroids and malnutrition in chronic renal failure. Perit Dial Int 1994;14: 362-365.
19. Dombros NV, Digenis GE, Soliman G, Oreopoulos DG: Anabolic steroids in the treatment of malnourished CAPD patients: A retrospective study. Perit Dial Int 1994;14:344-347.
20. Criqui MH, Heiss G, Cohn R, et al.: Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220-1225.
21. Neff MS, Eiser AR, Slifkin RF, et al.: Patients surviving 10 years of hemodialysis. Am J Med 1983;74:996-1004.
22. Eschbach JW, Adamson JW: Improvement in the anemia of chronic renal failure with fluoxymesterone. Ann Intern Med 1973;78:527-532.
23. Bernstein MS, Hunter RL, Yachnin S: Hepatoma and peliosis hepatis developing in a patient with Fanconi's anemia. N Engl J Med 1971;284:1135-1136.
24. Johnson FL, Feagler JR, Lerner KG, et al.: Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972;2:1273-1276.
25. Zevin D, Turani H, Cohen A, Levi J: Androgen-associated hepatoma in a hemodialysis patient. Nephron 1981;29:274-276.
26. von Hartitzsch B, Kerr DNS, Morley G, Marks B: Androgens in the anaemia of chronic renal failure. Nephron 1977;18:13-20.
27. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ: Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991;17:29-33.
28. Berns JS, Rudnick MR, Cohen RM: A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992;37:264-267.